Viquglip-50
Description_Effects
Viquglip-50 contains Vildagliptin 50 mg, an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to a class of medicines known as DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), which help improve blood sugar control in adults when diet and exercise alone are not enough. Vildagliptin works by regulating the levels of insulin and glucagon released by the pancreas. Specifically, it enhances the secretion of insulin in response to meals and reduces the amount of glucagon (a hormone that raises blood sugar) released when it's not needed. This dual mechanism helps to reduce both fasting blood glucose and postprandial (after meal) blood glucose levels, contributing to better overall glycemic control. Viquglip-50 is generally well-tolerated and has a low risk of causing hypoglycemia (low blood sugar), especially when used alone or in combination with medications that do not lower glucose levels excessively. It may be prescribed as monotherapy or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin. Maintaining good blood glucose levels is key to reducing the risk of diabetes-related complications such as kidney damage, vision loss, nerve problems, and cardiovascular disease. Along with proper medication, adopting a balanced diet, regular exercise, weight control, and routine monitoring plays a crucial role in the successful management of type 2 diabetes.
